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Abstract In skeletal muscle, glucose transport is stimulated by 
insulin, contractions and hypoxia. In this study, we used the 
phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin 
to examine whether (i) PI 3-kinase activity is necessary for stim- 
ulation of glucose transport by insulin in muscle, and (ii) PI 
3-kinase mediates a step in the pathway by which contractions/ 
hypoxia stimulate glucose transport. Wortmannin completely 
blocked insulin- and insulin-like growth factor-l-stimulated glu- 
cose transport in muscle. In contrast, wortmannin had no effect 
on the stimulation of glucose transport by contractions or hy- 
poxia, providing evidence that PI 3-kinase activity is not involved 
in the activation of glucose transport by these stimuli. 
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1. Introduction 
Glucose transport in skeletal muscle is stimulated via at least 
two distinct pathways. One pathway is activated by insulin and 
insulin mimetic agents, the other by contractions or hypoxia. 
That two pathways are involved is evidenced by the findings 
that the maximal effects of insulin and contractions [1,2] or 
hypoxia [3] on sugar transport are additive. The maximal effects 
of hypoxia and contractions are not additive [3], suggesting that 
these two stimuli activate glucose transport by the same mech- 
anism. Further evidence for two distinct pathways is provided 
by the finding that muscles of obese Zucker rats are resistant 
to the action of insulin, but not of contractions, on glucose 
transport [4]. The two pathways appear to have one or more 
steps in common, as the effects of both insulin and contrac- 
tions/hypoxia re inhibited by polymyxin [5] and sphingosine 
[6]. 
Binding of insulin to its receptor induces activation of  the 
insulin receptor's intrinsic tyrosine kinase activity, which, in 
turn, causes phosphorylation of several intracellular substrates, 
including insulin receptor substrate-1 (IRS-1) [7]. In its tyro- 
sine-phosphorylated form, IRS-1 acts as a docking protein for 
phosphatidylinositol 3-kinase (PI 3-kinase) [8]; association of 
PI 3-kinase with phosphorylated IRS-1 results in activation of 
the kinase [9,10]. Studies using wortmannin or LY294002, 
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potent inhibitors of PI 3-kinase [11,12], have shown that activa- 
tion of PI 3-kinase is essential for the stimulation of glucose 
transport in adipocytes [12-14]. In this context, the purpose of 
the present study was to determine, using the inhibitor wort- 
mannin, whether PI 3-kinase activity is (i) necessary for stimu- 
lation of glucose transport by insulin in skeletal muscle, and 
(ii) involved in the stimulation of glucose transport by contrac- 
tile activity and hypoxia. 
2. Materials and methods 
2.1. Materials 
Purified porcine insulin (Iletin II) was purchased from Eli Lilly and 
Co. (Indianapolis, IN). Recombinant human insulin-like growth factor- 
1 (IGF-1) was obtained from United States Biochemical Corp. (Cleve- 
land, OH). 2-Deoxy-D-[1,2-3H]glucose was purchased from American 
Radiolabeled Chemicals (St. Louis MO) and [U-~4C]mannitol was ob- 
tained from New England Nuclear (Boston, MA). Wortmannin, and 
all other reagents were obtained from Sigma (St. Louis, MO). 
2.2. Treatment of rats and muscle preparation 
Male Wistar rats weighing 80-120 g were provided with Purina Rat 
Chow and water ad libitum. Food was restricted to ~ 3 g after 5 : 00 p.m. 
the evening before the experiment. Rats were anesthetized by an in- 
traperitoneal injection of pentobarbital sodium (5 rag/100 g body 
weight) followed by removal of the epitrochlearis muscles. The suitabil- 
ity of the epitrochlearis, a small, thin forelimb muscle consisting pre- 
dominantly of type IIb fibers, for measurement of glucose transport in 
vitro has been demonstrated previously [1,15]. 
2.3. Muscle incubations 
Muscles were incubated initially for 30 min at 30°C in a Dubnoff 
shaking incubator in 2 ml of oxygenated Krebs-Henseleit buffer (KHB) 
supplemented with 2 mM sodium pyruvate, 36 mM mannitol and 0.1% 
radioimmunoassay grade bovine serum albumin (BSA) in the presence 
or absence of the indicated concentrations of wortmannin. Wortman- 
nin was added from a stock solution prepared in dimethyl sulfoxide 
(DMSO). Identical concentrations of DMSO were added to the control 
medium. The final concentration of DMSO in the medium never ex- 
ceeded 0.1%. Muscles were then incubated for an additional 30 min in 
identical medium with or without 12 nM insulin or 40 min with or 
without 25 nM IGF-1. 
2.4. Muscle stimulation 
Epitrochlearis muscles were stimulated to contract in vitro using a 
Grass model S11 stimulator as described previously [16]. Prior to and 
during stimulation, muscles were incubated in the presence or absence 
of wortmannin for 30 min as described above. Tetanic contractions 
were produced by stimulating at 100 Hz with 0.2 ms pulses for 10 s at 
a rate of 1 contraction/min for 10 min. 
2.5. Muscle hypoxia 
For studies of the effect of wortmannin on the maximal effects of 
hypoxia on glucose transport activity, muscles were initially incubated 
for 30 min in KHB gassed with 95% OJ5% CO2 in the presence or 
absence of wortmannin, then transferred to medium gassed with 95% 
N215% CO2 for 90 min. The hypoxic KHB contained 8 mM glucose, 
32 mM mannitol, and 0.1% BSA with or without wortmannin. Prior 
to measurement of glucose transport activity, muscles were transferred 
to oxygenated KHB containing 2 mM sodium pyruvate and 36 mM 
0014-5793195/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)00147-6 
52 A.D. Lee et al./FEBS Letters 361 (1995) 51-54 
mannitol, with or without wortmannin, for 10 rain to wash glucose out 
of the extracellular space. 
2.6. Measurement ofglucose transport activity 
2-Deoxy-D-glucose (2-DG) transport was measured by a modifica- 
tion of a previously described method [17]. After the initial incubation 
periods or electrical stimulation, all muscles were incubated for 20 min 
in 1.5 ml KHB containing 4 mM 2-deoxy-D-[1,2-3H]glucose (0.38 mCi/ 
mmol), 36 mM [U-~4C]mannitol (9/zCi/mmol), and 0.1% BSA. Wort- 
mannin and insulin or IGF-1 were added if they were present previ- 
ously. The incubation temperature was maintained at 30°C and the gas 
phase was 95% 02/5% CO2. Muscles were processed by boiling, and the 
extracellular space and intracellular 2-DG concentration ~umol. ml in- 
tracellular water -~. 20 min -1) were determined as previously described 
[15,17]. Under these conditions, 2-DG uptake accurately reflects glu- 
cose transport activity [17]. 
2.7. Statistical analysis 
All data are presented as means + S.E. The concentration-dependent 
effects of wortmannin on insulin-stimulated glucose transport were 
analyzed using a one-way analysis of variance (ANOVA). Post hoc 
analysis was performed using the Newman-Keuls test. Differences in 
basal or stimulated glucose transport activity measured in the presence 
or absence of wortmannin were assessed using Student's unpaired two- 
tailed t-test. 
3. Results 
Glucose transport activity stimulated by a maximally effec- 
tive concentration of insulin (12 nM) was inhibited by wort- 
mannin in a dose-dependent manner (Fig. 1). Insulin increased 
2-DG uptake ~ 5-fold; the presence of 0.1/zM wortmannin de- 
creased insulin-stimulated transport by 82%, while 0.5 /zM 
wortmannin completely inhibited the effect of  insulin. A simi- 
lar, complete inhibition of insulin-stimulated transport was ob- 
served with higher concentrations of wortmannin. The inhib- 
itory potency of wortmannin appears to be similar in adi- 
pocytes and skeletal muscle, as previous reports have shown 
that 0.1 to 1.0 pM wortmannin inhibits insulin-stimulated glu- 
cose transport in rat adipocytes by 80 to 100% [13,14]. 
The effects of wortmannin on basal, insulin- or IGF- l -st im- 
ulated glucose uptake are shown in Fig. 2. Wortmannin (2 pM) 
decreased basal 2-DG uptake slightly, but this reduction was 
not statistically significant. 2-DG uptake stimulated by maxi- 
mally effective concentrations of either insulin or IGF-1 was 
completely inhibited by 2/zM wortmannin, providing evidence 
for an essential role for PI 3-kinase activity in the activation of 
sugar transport in skeletal muscle by these two stimuli. 
Table 1 
Effect of wortmannin on basal, contraction- and hypoxia-stimulated 
2-DG transport in skeletal muscle 
Treatment 2-DG Transport 
(/tmol- ml -~- 20 min -~) 
Basal 
Wortmannin (2/zM) 
Contraction 
Contraction +wortmannin (2/IM) 
Hypoxia 
Hypoxia + wortmannin (2/zM) 
0.56 +_ 0.08 (6) 
0.45 + 0.04 (6) 
2.75 + 0.38 (7) 
2.46 + 0.35 (7) 
2.55 + 0.30 (11) 
2.32 _+ 0.27 (11) 
Values are means + S.E. for the number of muscles indicated in the 
parentheses. Epitrochlearis muscles were incubated for 30 min with or 
without 2 pM wortmannin. Muscles were then stimulated to contract 
(10 min) or incubated in hypoxic medium (90 min), in the presence or 
absence of wortmannin, prior to measurement of 2-DG transport as 
described in section 2. 
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Fig. 1. Effect of wortmannin concentration  maximally insulin-stim- 
ulated 2-DG transport rate. Epitrochlearis muscles were incubated for 
30 min at 30°C with the indicated concentrations of wortmannin, fol- 
lowed by a 30 min incubation in identical medium supplemented with 
12 nM insulin. The rate of 2-DG transport was then measured as 
described in section 2. The broken line represents ransport rate in the 
absence of insulin or wortmannin. Each point represents mean + S.E. 
for 8-14 muscles. *P < 0.01 vs. insulin alone. 
In contrast o the complete inhibition of insulin- or IGF-1- 
stimulated 2-DG uptake, the stimulation of glucose transport 
activity by hypoxia or muscle contractions was insensitive to 
the action of wortmannin (Table 1). This finding provides evi- 
dence that PI 3-kinase activity is not involved in the signaling 
pathway by which contractile activity and hypoxia activate 
glucose transport in skeletal muscle. 
4. Discussion 
There is increasing evidence to suggest hat both the insulin 
receptor and IRS-1 are required for most insulin-mediated met- 
abolic and mitogenic events [18-20]. An important point of 
divergence for the various insulin-mediated signaling pathways 
appears to be at the level of IRS-1, as activation of pp70 $6 
kinase has been shown to require signaling to PI 3-kinase 
through IRS-1, while the IRS-1-dependent activation of mito- 
gen activated protein kinase and pp90 $6 kinase appears to be 
PI 3-kinase independent [12]. A requirement for PI 3-kinase 
activity in the insulin-stimulation f Glut4 translocation [ 12,21] 
and glucose transport [12-14,21] has been demonstrated using 
two structurally distinct PI 3-kinase inhibitors, wortmannin 
and LY294002, but it was not known whether PI 3-kinase 
activity is required for the activation of glucose transport in 
muscle. Increased phosphorylation of IRS-1 and increased as- 
sociation of IRS-1 and PI 3-kinase have been demonstrated in
skeletal muscle following insulin stimulation [22,23]. These ob- 
servations, coupled with the complete inhibition of insulin- 
stimulated muscle glucose transport activity by wortmannin 
demonstrated in this study, indicate that the early signal- 
ing events by which insulin stimulates glucose transport in skel- 
etal muscle are similar to those previously characterized in 
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Fig. 2. Effect of wortmannin (2 JtM) on insulin- and IGF-l-stimulated 
2-DG transport. Epitrochlearis muscles were incubated for 30 min at 
30°C with 2 ~tM wortmannin, followed by a 30 min incubation in 
identical medium with or without 12 nM insulin, or a 40 rain incubation 
with or without 25 nM IGF-1. Glucose transport activity was assayed 
as described in section 2. Each bar represents mean + S.E. for (~11 
muscles. *P < 0.001 vs. control. 
adipocytes. Our findings provide evidence for an absolute re- 
quirement for PI 3-kinase activity in the insulin stimulation of 
glucose transport activity in skeletal muscle. 
Insulin and IGF-1 stimulate glucose transport activity in 
skeletal muscle through separate receptors, each containing 
protein tyrosine kinase activity [24]. Although the receptors are 
distinct, the maximal effects of insulin and IGF-1 on glucose 
uptake [24,25] or Glut4 translocation [25] in isolated skeletal 
muscle are not additive, suggesting a common intracellular 
signaling mechanism for the activation of glucose transport. 
This concept is supported by the recent finding that both insulin 
and IGF-1 stimulate increased tyrosine phosphorylation of 
IRS-1, and increased IRS-l-associated PI 3-kinase activity in 
32D myeloid progenitor cells coexpressing the insulin receptor 
and IRS-1 [20]. Our observations are consistent with the inter- 
pretation that the pathways for stimulation of glucose transport 
by insulin and IGF-1 in skeletal muscle converge at IRS-1, and 
that PI 3-kinase is involved in IGF-1 signaling. 
Studies on isolated rat skeletal muscle preparations have 
demonstrated that the maximal effects of insulin and contractile 
activity [1,2] or insulin and hypoxia [3] on glucose transport 
activity are completely additive, findings that have been inter- 
preted as evidence for a signaling pathway for insulin that is 
distinct from that for hypoxia or contractions. The lack of an 
inhibitory effect of wortmannin on contraction- or hypoxia- 
stimulated glucose uptake in the current study is consistent with 
this 'two pathway' concept. The finding that contraction- or 
hypoxia-stimulated glucose uptake were wortmannin-insensi- 
tive provides evidence that PI 3-kinase is not involved in the 
signaling cascade by which these stimuli activate muscle glucose 
transport. 
Activation of glucose transport activity by insulin, hypoxia, 
and contractile activity are all inhibited by polymyxin B [5] and 
sphingosine [6], indicating that the two pathways possess one 
or more common steps. The finding that the PI 3-kinase inhib- 
itor wortmannin completely inhibited insulin-stimulated, but 
had no effect on contraction- or hypoxia-stimulated, glucose 
transport activity indicates that any common elements of the 
signaling pathways leading to Glut4 translocation i skeletal 
muscle are downstream from PI 3-kinase. 
In conclusion, the ability of wortmannin to inhibit 2-DG 
uptake stimulated by insulin and IGF-1, but not by contrac- 
tions or hypoxia, provides further evidence that two distinct 
pathways exist for the activation of skeletal muscle glucose 
transport and that PI 3-kinase activity is not involved in the 
signaling pathway by which contractions or hypoxia stimulate 
glucose transport. In addition, our findings provide evidence 
for an essential role for PI 3-kinase activity in the activation of 
glucose transport by insulin or IGF-1 in skeletal muscle. 
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